Mobile

A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Resist...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-000422-39

A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide With or Without Deforolimus in Men With Asymptomatic, Metastatic Castrate-Resistant Prostate Cancer

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the efficacy of the combination of ridaforolimus and bicalutamide compared to placebo and bicalutamide by PSA decline within 12 weeks, a surrogate measurement of overall survival efficacy in prostate cancer therapy trials. To determine the safety and tolerability of ridaforolimus when combined with bicalutamide.

Critère d'inclusion

  • metastatic prostate cancer

Liens